S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.
Status:
Completed
Trial end date:
2021-03-29
Target enrollment:
Participant gender:
Summary
RATIONALE: Zoledronate, clodronate, or ibandronate may delay or prevent bone metastases in
patients with nonmetastatic breast cancer. It is not yet known whether zoledronate is more
effective than clodronate or ibandronate in treating breast cancer.
PURPOSE: This randomized phase III trial is studying zoledronate to see how well it works
compared to clodronate or ibandronate in treating women who have undergone surgery for stage
I, stage II, or stage III breast cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Southwest Oncology Group
Collaborators:
Cancer and Leukemia Group B Eastern Cooperative Oncology Group National Cancer Institute (NCI) NCIC Clinical Trials Group North Central Cancer Treatment Group NSABP Foundation Inc